Phaseline

Companies › Phathom Pharmaceuticals

Phathom Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 22 registered trials: 14 Phase 4, 4 Phase 2, 3 Phase 3, 1 Phase 1; Cardiovascular, Gastroenterology, Genitourinary, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vonoprazan
Potassium-transporting ATPase inhibitor
ATP4A, ATP4BPhase 3Symptomatic Non-erosive Gastroesophageal Reflux Disease; Eosinophilic Esophagitis; Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer; HELICOBACTER PYLORI INFECTIONS …Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07068607VonoprazanPhase 4Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic UlcerOncologyOct 2025
NCT06723197VonoprazanPhase 4HELICOBACTER PYLORI INFECTIONSInfectious diseaseOct 2025
NCT06723197VonoprazanPhase 4HELICOBACTER PYLORI INFECTIONSInfectious diseaseOct 2025
NCT07267260VonoprazanPhase 2Cirrhoses, LiverCardiovascularJan 2026
NCT06959368VonoprazanPhase 4Helicobacter Pylori InfectionInfectious diseaseMar 2026
NCT07344506VonoprazanPhase 4H. Pylori Gastrointestinal DiseaseInfectious diseaseMay 2026
NCT06564246VonoprazanPhase 4Gastroesophageal Reflux Disease (GERD)GastroenterologyAug 2026
NCT05957432VonoprazanPhase 2Helicobacter Pylori InfectionInfectious diseaseNov 2026
NCT06929962VonoprazanPhase 4Helicobacter Pylori InfectionInfectious diseaseDec 2026
NCT06851559VonoprazanPhase 2Eosinophilic EsophagitisGastroenterologyDec 2026
NCT04713670VonoprazanPhase 4H. Pylori InfectionInfectious diseaseDec 2026
NCT04713670VonoprazanPhase 4H. Pylori InfectionInfectious diseaseDec 2026
NCT04713670VonoprazanPhase 4H. Pylori InfectionInfectious diseaseDec 2026
NCT04713670VonoprazanPhase 4H. Pylori InfectionInfectious diseaseDec 2026
NCT07275827VonoprazanPhase 3HELICOBACTER PYLORI INFECTIONSInfectious diseaseDec 2026
NCT07293910VonoprazanPhase 2HELICOBACTER PYLORI INFECTIONSInfectious diseaseDec 2026
NCT07275632VonoprazanPhase 1Delayed Graft FunctionGenitourinaryDec 2026
NCT07752407VonoprazanPhase 3Symptomatic Non-erosive Gastroesophageal Reflux DiseaseGastroenterologyOct 2027
NCT05582174VonoprazanPhase 4Upper GI BleedingGastroenterologyJan 2028
NCT07788742VonoprazanPhase 4Barrett EsophagusGastroenterologyAug 2028
NCT06526455VonoprazanPhase 4Ulcers, GastricGastroenterologyJun 2029
NCT07576959VonoprazanPhase 3HELICOBACTER PYLORI INFECTIONSInfectious diseaseDec 2030

From the company's SEC filings

Cash of $185m on 2026-09-30; operating cash outflow about $21m a year; runway about 105 months at that burn, to Jun 2035; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ATP4A (1) ATP4B (1)

Companies with the same targets

Il-Yang Pharm. Carnot Laboratories AstraZeneca Cinclus Pharma Holding

Companies built like this

Carnot Laboratories Cinclus Pharma Holding Madrigal Pharmaceuticals Biocodex Polaris Group

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.